Talijanovic Melanija, Lopacinska-Jørgensen Joanna, Høgdall Estrid V
Department of Pathology, Herlev Hospital, University of Copenhagen, Herlev, Denmark.
Department of Pathology, Herlev Hospital, University of Copenhagen, Herlev, Denmark
Anticancer Res. 2025 Jan;45(1):11-26. doi: 10.21873/anticanres.17389.
BACKGROUND/AIM: Ovarian cancer (OC) is one of the leading gynecological causes of death among women. The current standard treatment for OC is debulking surgery followed by platinum-based chemotherapy treatments; however, despite initial success to treatment many patients experience relapses. Currently, there are no available tests to predict sensitivity or resistance to chemotherapy. The aim of this review is to investigate the literature regarding prediction of chemotherapy resistance in patients with OC using gene expression patterns.
The literature research on PubMed resulted in a total of 490 articles published from November 20, 2018, to November 20, 2024. We selected only the original studies that described the comparison of mRNA profiles between platinum-sensitive and -resistant OC patients. Studies were included if mRNA expression was measured in human tissue by gene expression microarray, RNA sequencing and quantitative real-time PCR.
Forty-four articles were included covering data from discovery cohorts obtained from hospitals and universities, as well as additional data obtained from online datasets from Gene Expression Omnibus and The Cancer Genome Atlas Program that provided either single- or multiple mRNA signatures that could discriminate between chemotherapy-sensitive and chemotherapy-resistant OC patients. OCs at all stages and histological subtypes were used but most articles included exclusively high-grade serous OC patients.
mRNA-based biomarkers to predict chemotherapy resistance in patients have not yet been clinically implemented, but many differentially expressed genes between chemotherapy-resistant and -sensitive patients have been reported, such as ABCG2, DOCK4, DUSP1, DUSP4, DUSP5, GADD45B, HELQ, HOXA9, KLF4, and NR4A1, which could be compelling biomarker candidates for further studies.
背景/目的：卵巢癌（OC）是女性妇科死亡的主要原因之一。OC的当前标准治疗方法是减瘤手术，随后进行铂类化疗；然而，尽管初始治疗取得成功，但许多患者仍会复发。目前，尚无可用的测试来预测对化疗的敏感性或耐药性。本综述的目的是研究关于使用基因表达模式预测OC患者化疗耐药性的文献。
对PubMed的文献研究共检索到2018年11月20日至2024年11月20日发表的490篇文章。我们仅选择了描述铂敏感和耐药OC患者之间mRNA谱比较的原始研究。如果通过基因表达微阵列、RNA测序和定量实时PCR在人体组织中测量mRNA表达，则纳入研究。
纳入了44篇文章，涵盖了从医院和大学获得的发现队列的数据，以及从基因表达综合数据库和癌症基因组图谱计划的在线数据集中获得的额外数据，这些数据集提供了可以区分化疗敏感和化疗耐药OC患者的单或多个mRNA特征。使用了所有阶段和组织学亚型的OC，但大多数文章仅纳入了高级别浆液性OC患者。
基于mRNA的预测患者化疗耐药性的生物标志物尚未在临床上实施，但已报道了许多化疗耐药和敏感患者之间差异表达的基因，如ABCG2、DOCK4、DUSP1、DUSP4、DUSP5、GADD45B、HELQ、HOXA9、KLF4和NR4A1，这些可能是进一步研究中引人注目的生物标志物候选者。
